Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Victoza contains the active ingredient liraglutide. Semaglutide and liraglutide belong to the same drug class, called glucagon-like peptide-1 (GLP-1) agonists. (A drug class is a group of ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

liraglutide is approved as Victoza for diabetes and Saxenda for obesity. And understanding the risks in adolescents, whose use of GLP-1 drugs has soared since they were approved for the age group ...

A new study has revealed that GLP-1 drugs, such as Novo Nordisk’s (NVO) semaglutide (Ozempic and Wegovy), may reduce the risk of developing Alzheimer’s disease in patients with type 2 diabetes.